Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael Medinger

Showing results (21-30 of 90) with videos related to

Pageof 9
Sort By:
International Journal of Molecular Sciences|November 11, 2011
Biomarkers in tumor angiogenesis and anti-angiogenic therapyAndreas Pircher, Wolfgang Hilbe, Isabel Heidegger, et al.
Therapeutische Umschau. Revue Therapeutique|March 12, 2020
[Diagnosis and Therapy of Acute Myeloid Leukemia]Michael Medinger, Dominik Heim, Jörg P Halter, et al.
Therapeutische Umschau. Revue Therapeutique|March 12, 2020
[Acute lymphoblastic leukemia - diagnosis and therapy]Michael Medinger, Dominik Heim, Claudia Lengerke, et al.
Anticancer Research|January 2, 2010
Antitumor and antiangiogenic activity of cediranib in a preclinical model of renal cell carcinomaMichael Medinger, Norbert Esser, Ute Zirrgiebel, et al.
Cancers|January 8, 2023
Blinatumomab in Relapsed/Refractory Burkitt LymphomaJeanne Bohler, Ulrike Bacher, Yara Banz, et al.
International Journal of Laboratory Hematology|November 27, 2019
Peripheral blood schistocytes in the acute phase after allogeneic or autologous stem cell transplantation assessed by digital microscopyMeropi Karakioulaki, Maria Martinez, Michael Medinger, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 19, 2007
Phase I and pharmacokinetic study of the (6-maleimidocaproyl)hydrazone derivative of doxorubicinClemens Unger, Brigitte Häring, Michael Medinger, et al.
Transplantation and Cellular Therapy|May 15, 2025
Busulfan Once Versus Four Times Daily: Impact on Pharmacokinetics, Organ Toxicities and Survival After Allogeneic Hematopoietic Stem Cell TransplantationClaire Seydoux, Jakob R Passweg, Dominik Heim, et al.
Anticancer Research|February 11, 2015
Angiogenic markers in plasma cell myeloma patients treated with novel agentsMichael Medinger, Jörg Halter, Dominik Heim, et al.
Therapeutische Umschau. Revue Therapeutique|March 12, 2020
[Hematopoietic cell transplantation - essentials on indication, patient referral and long term follow up]Jörg P Halter, Sabine Gerull, Christian Arranto, et al.
Pageof 9

Showing results (21-30 of 90) with videos related to

Sort By:
Pageof 9
International Journal of Molecular Sciences|November 11, 2011
Biomarkers in tumor angiogenesis and anti-angiogenic therapyAndreas Pircher, Wolfgang Hilbe, Isabel Heidegger, et al.
Therapeutische Umschau. Revue Therapeutique|March 12, 2020
[Diagnosis and Therapy of Acute Myeloid Leukemia]Michael Medinger, Dominik Heim, Jörg P Halter, et al.
Therapeutische Umschau. Revue Therapeutique|March 12, 2020
[Acute lymphoblastic leukemia - diagnosis and therapy]Michael Medinger, Dominik Heim, Claudia Lengerke, et al.
Anticancer Research|January 2, 2010
Antitumor and antiangiogenic activity of cediranib in a preclinical model of renal cell carcinomaMichael Medinger, Norbert Esser, Ute Zirrgiebel, et al.
Cancers|January 8, 2023
Blinatumomab in Relapsed/Refractory Burkitt LymphomaJeanne Bohler, Ulrike Bacher, Yara Banz, et al.
International Journal of Laboratory Hematology|November 27, 2019
Peripheral blood schistocytes in the acute phase after allogeneic or autologous stem cell transplantation assessed by digital microscopyMeropi Karakioulaki, Maria Martinez, Michael Medinger, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 19, 2007
Phase I and pharmacokinetic study of the (6-maleimidocaproyl)hydrazone derivative of doxorubicinClemens Unger, Brigitte Häring, Michael Medinger, et al.
Transplantation and Cellular Therapy|May 15, 2025
Busulfan Once Versus Four Times Daily: Impact on Pharmacokinetics, Organ Toxicities and Survival After Allogeneic Hematopoietic Stem Cell TransplantationClaire Seydoux, Jakob R Passweg, Dominik Heim, et al.
Anticancer Research|February 11, 2015
Angiogenic markers in plasma cell myeloma patients treated with novel agentsMichael Medinger, Jörg Halter, Dominik Heim, et al.
Therapeutische Umschau. Revue Therapeutique|March 12, 2020
[Hematopoietic cell transplantation - essentials on indication, patient referral and long term follow up]Jörg P Halter, Sabine Gerull, Christian Arranto, et al.
Pageof 9